Zhong Guo-cheng, Zhang Xiao-yu, Chen Jian, Sun Yi, Zhang Wen-hua, Gui Yong-zhong, Long Hai-xia, Zhu Bo
Department of Oncology, 452nd Hospital of People's Liberation Army, Chengdu 610021, China.
Zhonghua Zhong Liu Za Zhi. 2012 Jan;34(1):68-72.
The aim of this study was to discuss the clinical effectiveness of high intensity focused ultrasound (HIFU) combined with gemcitabine administered by intra-arterial infusion on intermediate and advanced pancreatic cancer.
Forty-eight patients with intermediate and advanced pancreatic cancer were divided into two groups. Twenty-four patients of the experimental group were treated by HIFU combined with gemcitabine, and 24 patients of the the HIFU group were treated by HIFU alone. Then the curative effect, extent of pain relief, and survival time were compared in the course of the treatment between the two groups.
As compared with those in the control group, the overall response rate, level of pain relief, and 12-month survival rate after therapy were higher and the median survival time was longer in the joint group (P < 0.05).
Ultrasound imaging, CT and associated tumor marker detection can make effective measurement to evaluate curative effect on pancreatic carcinoma. HIFU plus gemcitabine administered by intra-arterial infusion can improve the clinical therapeutic efficacy, pain relief, quality of life and long-term survival rate of patients with pancreatic cancer.
本研究旨在探讨高强度聚焦超声（HIFU）联合吉西他滨动脉灌注治疗中晚期胰腺癌的临床疗效。
将48例中晚期胰腺癌患者分为两组。实验组24例患者采用HIFU联合吉西他滨治疗，HIFU组24例患者仅采用HIFU治疗。然后比较两组治疗过程中的疗效、疼痛缓解程度和生存时间。
与对照组相比，联合组治疗后的总缓解率、疼痛缓解程度和12个月生存率更高，中位生存时间更长（P<0.05）。
超声成像、CT及相关肿瘤标志物检测可有效评估胰腺癌的治疗效果。HIFU联合吉西他滨动脉灌注可提高胰腺癌患者的临床治疗效果、缓解疼痛、改善生活质量和长期生存率。
